MX2020003361A - Combinacion de un inhibidor parp y un antagonista de union al eje pd-1. - Google Patents
Combinacion de un inhibidor parp y un antagonista de union al eje pd-1.Info
- Publication number
- MX2020003361A MX2020003361A MX2020003361A MX2020003361A MX2020003361A MX 2020003361 A MX2020003361 A MX 2020003361A MX 2020003361 A MX2020003361 A MX 2020003361A MX 2020003361 A MX2020003361 A MX 2020003361A MX 2020003361 A MX2020003361 A MX 2020003361A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- binding antagonist
- axis binding
- parp inhibitor
- parp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Esta invención se refiere a un método de tratar cáncer al administrar un inhibidor de PARP en combinación con un antagonista de unión al eje PD-1 a un paciente en necesidad del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762572024P | 2017-10-13 | 2017-10-13 | |
US201862697587P | 2018-07-13 | 2018-07-13 | |
PCT/US2018/055174 WO2019075032A1 (en) | 2017-10-13 | 2018-10-10 | COMBINATION OF A PARP INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003361A true MX2020003361A (es) | 2020-07-29 |
Family
ID=64049735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003361A MX2020003361A (es) | 2017-10-13 | 2018-10-10 | Combinacion de un inhibidor parp y un antagonista de union al eje pd-1. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200254091A1 (es) |
EP (1) | EP3694551A1 (es) |
JP (1) | JP2020536887A (es) |
KR (1) | KR20200071097A (es) |
CN (1) | CN111225685A (es) |
AU (1) | AU2018347331A1 (es) |
BR (1) | BR112020006371A2 (es) |
CA (1) | CA3078806A1 (es) |
IL (1) | IL273994A (es) |
MX (1) | MX2020003361A (es) |
RU (1) | RU2020113246A (es) |
TW (1) | TW201922288A (es) |
WO (1) | WO2019075032A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11274154B2 (en) * | 2016-10-06 | 2022-03-15 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
CA3163564A1 (en) * | 2019-12-31 | 2021-07-08 | Xiaokun SHEN | A drug combination for treating tumors and its application |
CA3177576A1 (en) * | 2020-05-04 | 2021-11-11 | Merck Sharp & Dohme Llc | Methods of treating cancer using a combination of a pd-1 antagonist, a chemoradiation therapy and a parp inhibitor |
WO2024074959A1 (en) | 2022-10-02 | 2024-04-11 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
CN102171214B (zh) | 2008-08-06 | 2015-06-24 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 |
CN102869258A (zh) | 2010-02-03 | 2013-01-09 | 生物马林药物股份有限公司 | 用于pten基因缺失相关疾病的治疗的聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 |
US8765945B2 (en) | 2010-02-08 | 2014-07-01 | Biomarin Pharmaceutical Inc. | Processes of synthesizing dihydropyridophthalazinone derivatives |
RU2598606C3 (ru) | 2010-10-21 | 2021-12-20 | МЕДИВЭЙШН ТЕКНОЛОДЖИЗ ЭлЭлСи | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она |
AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
CN105916846A (zh) | 2013-11-07 | 2016-08-31 | 麦迪韦逊科技有限公司 | 用于合成经保护的n-烷基三唑甲醛的三唑中间体 |
SI3102605T1 (sl) * | 2014-02-04 | 2019-04-30 | Pfizer Inc. | Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka |
EP3169361B1 (en) * | 2014-07-15 | 2019-06-19 | F.Hoffmann-La Roche Ag | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
EP3174855B1 (en) | 2014-07-31 | 2023-05-10 | Medivation Technologies LLC | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
CN107206088A (zh) * | 2014-12-05 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物 |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
KR20170132171A (ko) * | 2015-02-26 | 2017-12-01 | 메르크 파텐트 게엠베하 | 암 치료를 위한 pd1 / pdl1 저해제 |
US20170000885A1 (en) * | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
BR112018008503A2 (pt) | 2015-10-26 | 2018-10-23 | Medivation Tech Llc | método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer |
-
2018
- 2018-10-10 JP JP2020520007A patent/JP2020536887A/ja not_active Withdrawn
- 2018-10-10 CA CA3078806A patent/CA3078806A1/en not_active Abandoned
- 2018-10-10 US US16/754,485 patent/US20200254091A1/en not_active Abandoned
- 2018-10-10 AU AU2018347331A patent/AU2018347331A1/en not_active Abandoned
- 2018-10-10 WO PCT/US2018/055174 patent/WO2019075032A1/en unknown
- 2018-10-10 CN CN201880066544.4A patent/CN111225685A/zh active Pending
- 2018-10-10 BR BR112020006371-1A patent/BR112020006371A2/pt not_active IP Right Cessation
- 2018-10-10 MX MX2020003361A patent/MX2020003361A/es unknown
- 2018-10-10 KR KR1020207013511A patent/KR20200071097A/ko not_active Application Discontinuation
- 2018-10-10 EP EP18795891.3A patent/EP3694551A1/en active Pending
- 2018-10-10 RU RU2020113246A patent/RU2020113246A/ru unknown
- 2018-10-12 TW TW107135947A patent/TW201922288A/zh unknown
-
2020
- 2020-04-16 IL IL273994A patent/IL273994A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL273994A (en) | 2020-05-31 |
US20200254091A1 (en) | 2020-08-13 |
RU2020113246A (ru) | 2021-11-15 |
WO2019075032A1 (en) | 2019-04-18 |
EP3694551A1 (en) | 2020-08-19 |
JP2020536887A (ja) | 2020-12-17 |
BR112020006371A2 (pt) | 2020-09-29 |
TW201922288A (zh) | 2019-06-16 |
RU2020113246A3 (es) | 2021-11-15 |
CA3078806A1 (en) | 2019-04-18 |
KR20200071097A (ko) | 2020-06-18 |
AU2018347331A1 (en) | 2020-04-09 |
CN111225685A (zh) | 2020-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001757A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. | |
ZA202110554B (en) | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors | |
IL262561B (en) | Methods for treating skin cancer by administering a pd-1 inhibitor | |
MX2018014435A (es) | Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer. | |
MX2018016193A (es) | Métodos para el tratamiento del cáncer de ovario. | |
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2020003361A (es) | Combinacion de un inhibidor parp y un antagonista de union al eje pd-1. | |
EA201490369A1 (ru) | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek | |
IL254133B (en) | Combination of pd-1 antagonist and eribulin for cancer treatment | |
MX2015014591A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
SA515370011B1 (ar) | طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين | |
HK1244436A1 (zh) | 治療癌症的hsp90抑制劑和pd-1抑制劑的組合療法 | |
MX2017009246A (es) | Farmaco de combinacion. | |
MX2019013862A (es) | Terapia de combinacion. | |
MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
MX2020006224A (es) | Metodos y terapia combinada para el tratamiento del cancer. | |
MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. | |
MX2020006125A (es) | Uso de un anticuerpo biespecifico de cea cd3 y un antagonista de la union al eje de pd-1 en un regimen de dosificacion para tratar el cancer. |